0001437749-25-008774.txt : 20250321 0001437749-25-008774.hdr.sgml : 20250321 20250321172022 ACCESSION NUMBER: 0001437749-25-008774 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250321 DATE AS OF CHANGE: 20250321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OPKO HEALTH, INC. CENTRAL INDEX KEY: 0000944809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 752402409 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-33528 FILM NUMBER: 25761592 BUSINESS ADDRESS: STREET 1: 4400 BISCAYNE BLVD. CITY: MIAMI STATE: FL ZIP: 33137 BUSINESS PHONE: 305-575-4181 MAIL ADDRESS: STREET 1: 4400 BISCAYNE BLVD. CITY: MIAMI STATE: FL ZIP: 33137 FORMER COMPANY: FORMER CONFORMED NAME: Opko Health, Inc. DATE OF NAME CHANGE: 20070621 FORMER COMPANY: FORMER CONFORMED NAME: eXegenics Inc DATE OF NAME CHANGE: 20040505 FORMER COMPANY: FORMER CONFORMED NAME: EXEGENICS INC DATE OF NAME CHANGE: 20011114 10-K/A 1 opk20241231_10ka.htm FORM 10-K/A opk20241231_10ka.htm
true 0000944809 0000944809 2024-01-01 2024-12-31 0000944809 2024-06-30 0000944809 2025-01-31 iso4217:USD xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
 
FORM 10-K/A
Amendment No. 1
 
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended December 31, 2024.
 
OR
 
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from to .
Commission file number 001-33528
 
 
OPKO Health, Inc.
(Exact Name of Registrant as Specified in Its Charter)
 
 
Delaware
75-2402409
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification No.)
 
4400 Biscayne Blvd.
Miami, FL 33137
(Address of Principal Executive Offices) (Zip Code)
(305) 575-4100
(Registrant’s Telephone Number, Including Area Code)
 
Securities registered pursuant to section 12(b) of the Act:
     
Title of Each Class
Trading Symbol
Name of Each Exchange on Which Registered
Common Stock, $.01 par value per share
OPK
NASDAQ Global Select Market
 
 
Securities registered pursuant to section 12(g) of the Act:
 
None
 
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☒  No  ☐
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐    No  ☒
 
 
 
Table of Contents
 
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
   
Emerging growth company
☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
 
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
 
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive- based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No  ☒
 
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, as of the last business day of the registrant’s most recently completed second fiscal quarter was: $414,913,527.
 
As of January 31, 2025, the registrant had 671,550,270 shares of its common stock, par value $0.01 per share (“Common Stock”) outstanding.
 
Documents Incorporated by Reference
 
Portions of the registrant’s definitive proxy statement for its 2025 Annual Meeting of Stockholders are incorporated by reference in Items 10, 11, 12, 13, and 14 of Part III of this Annual Report on Form 10-K.
 
 
 
Table of Contents
 
Explanatory Note
 
OPKO Health, Inc., a Delaware corporation (the “Company”), is filing this Amendment No. 1 on Form 10-K/A (the “Amendment” or “Form 10-K/A”) to amend and restate Part III, Item 10. Directors, Executive Officers and Corporate Governance to include XBRL tagging and to amend and restate Part IV, Item 15, Exhibits and Financial Statement Schedules of its Annual Report on Form 10-K for the year ended December 31, 2024 originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 3, 2025 (the “Original 10-K”), which inadvertently included the OPKO Health, Inc. Related Party Transaction Policy as Exhibit 19.1 instead of the Company’s Insider Trading Policy. Accordingly, Part IV, Item 15, Exhibits and Financial Statement Schedules has been amended and restated in its entirety to include the Company’s Insider Trading Policy as Exhibit 19.1.
 
In accordance with Rules 12b-15 and 13a-14 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we have also amended Part IV, Item 15, Exhibits and Financial Statement Schedules to include currently dated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from our principal executive officer and principal financial officer. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. Similarly, because no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted.
 
Except as described above, this Amendment does not amend, update or change any other disclosures in the Original 10-K. In addition, the information contained in this Amendment does not reflect events occurring after the filing of the Original 10-K and does not modify or update the disclosures therein, except as specifically identified above.
 
Ernst & Young LLP
PCAOB ID No. 42
Miami, Florida
 
 
Table of Contents
   
  
TABLE OF CONTENTS
 
 
Page
Part III.   4
Item 10. Directors, Executive Officers and Corporate Governance 4
Part IV.
  
Item 15.
Signatures
  
Certifications
   11
EX-31.1
    
EX-31.2
    
EX-101. INS XBRL Instance Document
  
EX-101.SCH XBRL Taxonomy Extension Schema Document
  
EX-101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
  
EX-101.DEF XBRL Taxonomy Extension Definition Linkbase Document
  
EX-101.LAB XBRL Taxonomy Extension Label Linkbase Document
  
EX-101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
  
 
 
 
 
 
3
Table of Contents
PART III.
 
Except to the extent included below, the information required in Items 10 (Directors, Executive Officers and Corporate Governance), Item 11 (Executive Compensation), Item 12 (Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters), Item 13 (Certain Relationships and Related Transactions, and Director Independence), and Item 14 (Principal Accounting Fees and Services) is incorporated by reference to the Company’s definitive proxy statement for the 2025 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of December 31, 2024.
 
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
 
Code of Ethics
 
We have adopted a Code of Business Conduct and Ethics. We require all employees, including our principal executive officer, principal financial officer, principal accounting officer and other senior officers and our employee directors, to read and to adhere to the Code of Business Conduct and Ethics in discharging their work-related responsibilities. Employees are required to report any conduct that they believe in good faith to be an actual or apparent violation of the Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics is available on our website at http://www.OPKO.com. Any amendment to, or waivers of, the Code of Business Conduct and Ethics will be disclosed on our website promptly following the date of such amendment or waiver.
 
Insider Trading Policy
 
We have adopted an Insider Trading Policy which governs the purchase, sale and/or any other dispositions of our securities by the Company and its directors, officers and employees and is reasonably designed to promote compliance with insider trading laws, rules and regulations and applicable exchange listing standards. A copy of our Insider Trading Policy is filed as Exhibit 19.1 to this Annual Report on Form 10-K.
 
4
Table of Contents
 
PART IV.
 
Item 15.    EXHIBITS, FINANCIAL STATEMENT SCHEDULES.
 
 
(1)
Exhibits: See Index to Exhibits below.
 
 
INDEX TO EXHIBITS
 
Exhibit
Number
Description
   
   
   
2.4++ Asset Purchase Agreement, dated as of March 27, 2024 by and among BioReference Health, LLC, OPKO Health, Inc. and Laboratory Corporation of America Holdings, filed with the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 28, 2024, and incorporated herein by reference.
   
   
   
   
   
3.5 Composite Amended and Restated Certificate of Incorporation of OPKO Health, Inc., filed with the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2024, and incorporated herein by reference.
 
5
Table of Contents
 
   
   
   
   
4.5 Indenture, dated January 9, 2024, by and between OPKO Health, Inc. and U.S. Bank Trust Company, National Association, as Trustee, filed with the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 9, 2024, and incorporated herein by reference.
   
4.6 Form of 3.75% Convertible Senior Note due 2029, incorporated by reference to Exhibit A of the Indenture filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 9, 2024.
   
   
   
   
Exclusive License Agreement by and between TESARO, Inc. and OPKO Health, Inc. dated December 10, 2010, filed with the Company’s Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on July 28, 2011, and incorporated herein by reference.
 
   
   
   
 
6
Table of Contents
 
   
   
   
   
   
   
   
   
   
   
 
 
7
Table of Contents
 
Settlement Agreement between United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General of the Department of Health and Human Services, and the Defense Health Agency, acting on behalf of the TRICARE Program, the Commonwealth of Massachusetts, acting through the Medicaid Fraud Division of the Office of Attorney General and on behalf of the Executive Office of Health and Human Services, limited to its role as the single state agency for Medicaid, the State of Connecticut, acting through the Attorney General of the State of Connecticut, BioReference Health, LLC and OPKO Health, Inc., and Jean Marie Crowley, effective July 14, 2022, filed with the Company’s Current Report on Form 8⁃K filed with the Securities and Exchange Commission on July 15, 2022, and incorporated herein by reference.
 
10.21 Form of Amended 5% Convertible Promissory Note dated February 10, 2023, filed as Exhibit 10.22 filed with the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 27, 2023, and incorporated herein by reference. 
   
10.22 Waiver and Amendment No. 2 to the Amended and Restated Credit Agreement, dated June 29, 2023, by and among BioReference Health, LLC, certain of its subsidiaries, and JPMorgan Chase Bank, N.A., filed with the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 3, 2023 for the Company's three-month period ended June 30, 2023, and incorporated herein by reference.
   
10.23++ License and Research Collaboration Agreement by and between ModeX Therapeutics, Inc., OPKO Health, Inc. (with respect to certain sections), and Merck Sharp & Dohme LLC dated March 7, 2023, filed with the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 3, 2023 for the Company's three-month period ended March 31, 2023, and incorporated herein by reference.
   
10.24++ Purchase Agreement, dated January 4, 2024, by and between the Company and J.P. Morgan Securities LLC, as representative of the Initial Purchasers named therein, filed with the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 9, 2024, and incorporated herein by reference.
   
10.25++ Convertible Note Purchase Agreement, dated as of January 4, 2024, by and among the Company and certain investors, including Frost Gamma Investments Trust and Jane H. Hsiao, Ph.D., MBA, filed with the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 9, 2024, and incorporated herein by reference.
   
10.26+++ Note Purchase Agreement dated July 17, 2024 by and among the Company, certain purchasers party thereto, OPKO Biologics Limited, Eirgen Pharma Ltd. and HCR Injection SPV, LLC as agent, filed with the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024, and incorporated herein by reference.
   
10.27 Form of Note dated July 17, 2024, filed with the Company's Quarterly Report on Form 10Q filed with the Securities and Exchange Commission on August 7, 2024, and incorporated herein by reference.
   
19.1** OPKO Health, Inc. Insider Trading Policy.
   
   
 
8
Table of Contents
 
 
 
   
 
   
   
   
97.1 OPKO Health, Inc. Mandatory Recovery of Compensation Policy filed with the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2024, and incorporated herein by reference. 
   
101.SCH
XBRL Taxonomy Extension Schema Document
   
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
   
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
   
101.LAB
XBRL Taxonomy Extension Label Linkbase Document
   
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
* Denotes management contract or compensatory plan or arrangement.
   
** Filed herewith.
   
+ Certain confidential material contained in the document has been omitted and filed separately with the Securities and Exchange Commission.
   
++ Pursuant to Item 601(a)(5) of Regulation S-K, schedules and similar attachments to this exhibit have been omitted because they do not contain information material to an investment or voting decision and such information is not otherwise disclosed in such exhibit. The Company will supplementally provide a copy of any omitted schedule or similar attachment to the U.S. Securities and Exchange Commission or its staff upon request.
   
+++ Pursuant to Item 601(b)(10)(iv) of Regulation S-K, portions of this exhibit have been omitted because the Company customarily and actually treats the omitted portions as private or confidential, and such portions are not material. The Company will supplementally provide a copy of an unredacted copy of this exhibit to the U.S. Securities and Exchange Commission or its staff upon request.
   
 
 
9
Table of Contents
SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Date:  March 21, 2025
OPKO HEALTH, INC.
     
 
By:
/s/ Adam Logal
   
Adam Logal
    Senior Vice President, Chief Financial Officer, 
   
Chief Accounting Officer
 
10
Table of Contents
 
ExhibitNumber
Description
   
19.1 OPKO Health, Inc. Insider Trading Policy.
   
 
   
 
   
Exhibit 101.INS
Inline XBRL Instance Document
   
Exhibit 101.SCH
Inline XBRL Taxonomy Extension Schema Document
   
Exhibit 101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
   
Exhibit 101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document
   
Exhibit 101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document
   
Exhibit 101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document
   
Exhibit 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
 
 
11
EX-19.1 2 ex_792993.htm EXHIBIT 19.1 ex_792993.htm

Exhibit 19.1

 

OPKO HEALTH, INC.

 

INSIDER TRADING POLICY

(Revised July 22, 2008)

 

 

This Insider Trading Policy provides guidelines to all personnel (“Restricted Persons”), including employees (both domestic and international), directors and officers, of OPKO Health, Inc. and its subsidiaries (the “Company”), with respect to transactions in the Company’s securities and the handling of material non-public information about the Company and the companies with which it does business. In the discretion of the Company’s Compliance Officer, this Insider Trading Policy may also apply to consultants to and contractors of the Company and its subsidiaries who may come into possession of such material non-public information as a result of their work for or on behalf of the Company.

 

For purposes of this Insider Trading Policy, the Company’s securities include common stock, options to purchase common stock and any other securities the Company may issue from time to time, such as preferred stock, warrants, convertible debentures and debt securities. The Company’s securities also include derivative securities relating to the Company’s securities, even if not issued by the Company, such as exchange-traded options.

 

The Company’s directors, officers and certain designated employees are subject to additional limitations, including pre-clearance and blackout restrictions, described separately in the Company’s Pre-clearance and Blackout Policy.

 

I.         Policy

 

It is the policy of the Company to comply with all insider trading laws and regulations.

 

II.      Responsibility

 

Restricted Persons may create, use or have access to material information about the Company that is not generally available to the investing public (such information is referred to in this Insider Trading Policy as “material non-public information,” as explained in more detail below). Each Restricted Person has an important ethical and legal obligation to maintain the confidentiality of such information and not to engage in any transactions in the Company’s securities while in possession of material non-public information of the Company. Each Restricted Person and the Company may be subject to severe civil and criminal penalties as a result of unauthorized disclosure of material nonpublic information of the Company or trading in the Company’s securities while in possession of material non-public information of the Company.

 

The Compliance Officer or, in the Compliance Officer’s absence, the Chief Accounting Officer, is responsible for the administration of this Insider Trading Policy. For purpose of this Insider Trading Policy, the Company’s Deputy General Counsel shall be the Compliance Officer.

 

 
 

 

III.     Guidelines

 

1.         Prohibition. Every Restricted Person who is aware of material non-public information is prohibited from:

 

  (a) buying or selling the Company’s securities while in possession of material non-public information regarding the Company;
     
  (b) communicating such material non-public information to third parties other than those who need to know such information in connection with doing business with or for the Company, as authorized by the Company;
     
  (c) recommending the purchase or sale of the Company’s securities while in the possession of material information that has not been publicly disclosed by the Company; and
     
  (d) assisting anyone engaged in any of the above activities.

 

This prohibition also applies to information about, and to the trading of securities of, other companies (e.g., customers or suppliers) with which the Company has a relationship until such information becomes public or is no longer material.

 

This Insider Trading Policy does not apply to the exercise of employee stock options.  However, this Insider Trading Policy does apply to the sale of securities of the Company as part of a broker-assisted cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option.

 

There are no exceptions to this Insider Trading Policy. Engaging in transactions in the Company’s securities that are otherwise necessary for personal reasons, such as personal financial commitments, are still prohibited if you possess material non-public information of the Company.

 

2.         Transactions by Family Members; Entities Controlled by You. The prohibitions outlined in this Insider Trading Policy also apply to any “family members,” who reside with you, anyone else who lives in your household and any other family member whose transactions in the Company’s securities are directed by you or subject to your influence or control and any entities under your control. “Family Members” includes your spouse, any child, stepchild, grandchild, parent, stepparent, grandparent, sibling, mother or father-in-law, son or daughter-in-law, or brother or sister-in-law (as well as other adoptive relationships) with whom you share a household. The Company will hold you responsible for the conduct of your family members, anyone who lives in your household and any entities under your control.

 

3.         Tipping Information to Others. You may not disclose any material non-public information to others, including your family members, friends or social acquaintances. This prohibition applies whether or not you receive any benefit from the other person’s use of that information. The Securities and Exchange Commission (the “SEC”) has imposed large civil and criminal penalties on the person providing the tip, the individual receiving the tip (the “tippee”) and all those to whom the tippee, in turn, gives the information, even when the disclosing person did not profit from the trading.

 

 

2
 

 

4.         Material Non-Public Information.

 

Material Information. Information is considered “material” if a reasonable investor would likely consider it important in making a decision to purchase, hold or sell the Company’s securities (e.g., information regarding a possible merger or acquisition involving the Company, the introduction of important products or major marketing changes). In addition, any information that could affect the market for the Company’s securities is material. It is important to keep in mind that material information need not be certain or definitive information. Even information concerning events, actions, results, etc. that may happen can be considered material under certain circumstances.

 

Non-public Information. Non-public information is any information that has not been disclosed generally to the investing public. Disclosure by press release or in the Company’s periodic reports filed with the SEC is necessary to make the information public. However, even after the Company has released information to the public, you should generally allow at least two (2) full trading days (that is, days on which the American Stock Exchange, the other national stock exchanges and Nasdaq are open for trading) for the investing public to absorb and evaluate the information before you trade in the Company’s securities.

 

Although it is not possible to list all types of material information, the following are a few examples of information that is particularly sensitive and should be treated as material:

 

  ● quarterly or annual financial results;
  ● Significant contracts and technology licenses or any amendments or termination thereof;
  ● projections of future earnings or losses, or other earnings guidance;
  ● changes in management;
  ● significant increase or decrease in financial results;
  ● changes in auditors;
  ● significant actions by regulatory bodies or commencement of major litigation;
  ● the introduction, or obsolescence, of important products or services;
  ● changes in estimates of earnings or sales;
  ● major marketing changes;
  ● offerings of additional securities;
  ● borrowings or other financial transactions;
  ● clinical trial results or data;
  ● unusual gains or losses in major operations;
  ● stock splits or securities offerings;
  ● possible mergers, acquisitions or joint ventures;
  ● purchase or sale of a significant asset;
  ● significant labor disputes;
  ● financial liquidity problems; and
  ● establishment of a repurchase program for the Company’s securities.

 

3
 

 

If you have any question as to whether particular information is material or non-public, you should not trade or communicate the information to anyone without prior approval by the

Compliance Officer.

 

5.         Inadvertent Disclosure. If material non-public information is inadvertently disclosed by any Restricted Person to a person outside the Company who is not obligated to keep the information confidential, you should immediately report all the facts to the Compliance Officer, or such other individual designated by the Company so that the Company may take appropriate remedial action. Under the SEC’s rules, the Company generally has only 24 hours after learning of an inadvertent disclosure of material non-public information to publicly disclose such information, if necessary.

 

6.         Short-term, Speculative Transactions. The Company has determined that there is a substantial likelihood for the appearance of improper conduct by Restricted Persons when they engage in short-term or speculative securities transactions. Therefore, Restricted Persons are prohibited from engaging in any of the following activities involving the Company’s securities, except with the prior written consent of the Compliance Officer:

 

  (a) purchasing the Company’s securities on margin;
     
  (b) pledging Company securities;
     
  (c) short sales;
     
  (d) buying or selling puts or calls in connection with the Company’s securities; and
     
  (e) engaging in derivative transactions relating to the Company’s securities (e.g., exchange traded options, etc.)/

 

7.         Further Prohibition. From time to time, effective immediately upon notice or as otherwise provided by the Company, the Company may determine that other types of transactions, or all transactions, by Company personnel in the Company’s securities shall be prohibited or shall be permitted only with the prior written consent of the Compliance Officer.

 

8.         Confidentiality Guidelines. To provide more effective protection against the inadvertent disclosure of material non-public information about the Company or the companies with which it does business, the Company has adopted the following guidelines in addition to the prohibition in paragraph 3 above. These guidelines are not intended to be exhaustive. Additional measures to secure the confidentiality of information should be undertaken as deemed necessary under the circumstances. If you have any doubt as to your responsibilities with respect to confidential information, please seek clarification and guidance from the Compliance Officer before you act. Do not try to resolve any uncertainties on your own.

 

The following guidelines establish procedures with which every Restricted Person must comply in order to maximize the security of confidential information:

 

  (a) Do not discuss any Company matter in public places, such as elevators, hallways, restrooms or eating facilities, where conversations might be overheard.
     
  (b) Use passwords to restrict access to the information on computers.
     
  (c) Limit access to particular physical areas where material non-public information is likely to be documented or discussed.
     
  (d) Maintain records in accordance with the Company’s document retention policies in effect from time to time.

 

4
 

 

9.         Authorized Disclosure of Material Non-Public Information. Under certain circumstances, the Compliance Officer may authorize the immediate release of material non- public information. If disclosure is authorized, the form and content of all public disclosures shall be approved by the Compliance Officer pursuant to the terms of the Company’s applicable policies and procedures. In the case of material non-public information that is not disclosed, such information is not to be disclosed or discussed except on a strict “need-to-know” basis. All requests for information, comments, or interviews (other than routine product inquiries) made to any Restricted Person of the Company should be directed immediately to the Compliance Officer, who will clear all proposed responses in accordance with applicable law and the Company’s policies and procedures. It is anticipated that most questions raised can be answered by the Compliance Officer or another company representative to whom the Compliance Officer refers the request. Restricted Persons should not respond to such requests directly, unless expressly instructed otherwise by the Compliance Officer. In particular, great care should be taken not to comment on the Company’s expected future financial results without the express instruction by the Compliance Officer. If the Company wishes to give some direction to investors or securities professionals, it must do so only in compliance with the Company’s policies and applicable law. All communications with representatives of the media and securities analysts shall be directed to the Compliance Officer.

 

10.         Company Assistance. If you have any questions about specific information or proposed transactions, or as to the applicability or interpretation of this Insider Trading Policy or the propriety of any desired action, you are encouraged to contact the Compliance Officer.

 

11.         Post-Termination Transactions. The restrictions set forth in this Insider

Trading Policy continue to apply to your transactions in the Company’s securities even after the termination of your employment or term in office, as applicable, for such period as the Compliance Officer shall determine you are likely to be in possession of material non-public information about the Company. If you are in possession of material non-public information when your employment terminates, you may not trade in the Company’s securities until that information has become public or is no longer material.

 
5
 EX-31.1 3 ex_792996.htm EXHIBIT 31.1 ex_792996.htm

Exhibit 31.1

 

CERTIFICATIONS

I, Phillip Frost, certify that:

 

 

(1)

I have reviewed this Annual Report on Form 10-K/A of OPKO Health, Inc.; and

 

 

(2)

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

 

Date:  March 21, 2025

/s/Phillip Frost, M.D.
  Phillip Frost, M.D.
 

Chief Executive Officer

 

 
 EX-31.2 4 ex_792997.htm EXHIBIT 31.2 ex_792997.htm

Exhibit 31.2

 

CERTIFICATIONS

I, Adam Logal, certify that:

 

 

(1)

I have reviewed this Annual Report on Form 10-K/A of OPKO Health, Inc.; and

 

 

(2)

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

 

Date:  March 21, 2025 /s/ Adam Logal
 

Adam Logal
 

Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer

 

 
 EX-101.SCH 5 opk-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 6 opk-20241231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 opk-20241231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Current Fiscal Year End Date Document, Fiscal Period Focus Document, Fiscal Year Focus Document, Type Document, Annual Report Document, Period End Date Document, Transition Report Entity, File Number Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Well-known Seasoned Issuer Entity, Voluntary Filers Entity, Current Reporting Status Entity, Interactive Data, Current Entity, Filer Category Entity, Small Business Entity, Emerging Growth Company ICFR Auditor Attestation Flag Document, Financial Statement Error Correction Flag Entity, Shell Company Entity, Public Float Entity, Common Stock Shares, Outstanding Amendment Description Auditor Name Auditor Firm ID Auditor Location Amendment Flag Entity, Central Index Key Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted [Flag] Insider Trading Policies and Procedures Adopted EX-101.PRE 8 opk-20241231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2024
Jan. 31, 2025
Jun. 30, 2024
Document Information [Line Items]      
Entity, Registrant Name OPKO Health, Inc.    
Current Fiscal Year End Date --12-31    
Document, Fiscal Period Focus FY    
Document, Fiscal Year Focus 2024    
Document, Type 10-K/A    
Document, Annual Report true    
Document, Period End Date Dec. 31, 2024    
Document, Transition Report false    
Entity, File Number 001-33528    
Entity, Incorporation, State or Country Code DE    
Entity, Tax Identification Number 75-2402409    
Entity, Address, Address Line One 4400 Biscayne Blvd.    
Entity, Address, City or Town Miami    
Entity, Address, State or Province FL    
Entity, Address, Postal Zip Code 33137    
City Area Code 305    
Local Phone Number 575-4100    
Title of 12(b) Security Common Stock    
Trading Symbol OPK    
Security Exchange Name NASDAQ    
Entity, Well-known Seasoned Issuer Yes    
Entity, Voluntary Filers No    
Entity, Current Reporting Status Yes    
Entity, Interactive Data, Current Yes    
Entity, Filer Category Large Accelerated Filer    
Entity, Small Business false    
Entity, Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document, Financial Statement Error Correction Flag false    
Entity, Shell Company false    
Entity, Public Float     $ 414,913,527
Entity, Common Stock Shares, Outstanding   671,550,270  
Amendment Description OPKO Health, Inc., a Delaware corporation (the “Company”), is filing this Amendment No. 1 on Form 10-K/A (the “Amendment” or “Form 10-K/A”) to amend and restate Part III, Item 10. Directors, Executive Officers and Corporate Governance to include XBRL tagging and to amend and restate Part IV, Item 15, Exhibits and Financial Statement Schedules of its Annual Report on Form 10-K for the year ended December 31, 2024 originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 3, 2025 (the “Original 10-K”), which inadvertently included the OPKO Health, Inc. Related Party Transaction Policy as Exhibit 19.1 instead of the Company’s Insider Trading Policy. Accordingly, Part IV, Item 15, Exhibits and Financial Statement Schedules has been amended and restated in its entirety to include the Company’s Insider Trading Policy as Exhibit 19.1.   In accordance with Rules 12b-15 and 13a-14 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we have also amended Part IV, Item 15, Exhibits and Financial Statement Schedules to include currently dated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from our principal executive officer and principal financial officer. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. Similarly, because no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted.   Except as described above, this Amendment does not amend, update or change any other disclosures in the Original 10-K. In addition, the information contained in this Amendment does not reflect events occurring after the filing of the Original 10-K and does not modify or update the disclosures therein, except as specifically identified above.    
Auditor Name Ernst & Young LLP    
Auditor Firm ID 42    
Auditor Location Miami, Florida    
Amendment Flag true    
Entity, Central Index Key 0000944809    
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Policies and Procedures
 12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 3 39 1 false 0 0 false 2 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.opk.com/20241231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 995447 - Disclosure - Insider Trading Policies and Procedures Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc Insider Trading Policies and Procedures Notes 2 false false All Reports Book All Reports opk-20241231.xsd opk-20241231_def.xml opk-20241231_lab.xml opk-20241231_pre.xml opk20241231_10ka.htm http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "opk20241231_10ka.htm": { "nsprefix": "opk", "nsuri": "http://www.opk.com/20241231", "dts": { "schema": { "local": [ "opk-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-8k-sub-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-cr-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "opk-20241231_def.xml" ] }, "labelLink": { "local": [ "opk-20241231_lab.xml" ] }, "presentationLink": { "local": [ "opk-20241231_pre.xml" ] }, "inline": { "local": [ "opk20241231_10ka.htm" ] } }, "keyStandard": 39, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 0, "elementCount": 54, "unitCount": 2, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 38, "http://xbrl.sec.gov/ecd/2024": 1 }, "report": { "R1": { "role": "http://www.opk.com/20241231/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d202510KA", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "div", "body", "html" ], "reportCount": 1, "baseRef": "opk20241231_10ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d202510KA", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "div", "body", "html" ], "reportCount": 1, "baseRef": "opk20241231_10ka.htm", "first": true, "unique": true } }, "R2": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "2", "firstAnchor": { "contextRef": "d202510KA", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "opk20241231_10ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d202510KA", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "opk20241231_10ka.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r3", "r4", "r6" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r3", "r4", "r6" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r3", "r4", "r6" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r3", "r4", "r6" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Financial Statement Error Correction Flag", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r3", "r4", "r6", "r12" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r11" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Common Stock Shares, Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Interactive Data, Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r15" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r3", "r4", "r6" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r5", "r13" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r5", "r13" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "cyd_MaterialCybersecurityIncidentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentAbstract", "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Abstract]" } } }, "auth_ref": [ "r7", "r8" ] }, "cyd_MaterialCybersecurityIncidentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentAxis", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Axis]" } } }, "auth_ref": [ "r7", "r8" ] }, "cyd_MaterialCybersecurityIncidentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentDomain", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Domain]" } } }, "auth_ref": [ "r7", "r8" ] }, "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]" } } }, "auth_ref": [ "r7", "r9" ] }, "cyd_MaterialCybersecurityIncidentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Line Items]" } } }, "auth_ref": [ "r7", "r10" ] }, "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]" } } }, "auth_ref": [ "r7", "r10" ] }, "cyd_MaterialCybersecurityIncidentNatureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentNatureTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Nature [Text Block]" } } }, "auth_ref": [ "r7", "r10" ] }, "cyd_MaterialCybersecurityIncidentScopeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentScopeTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Scope [Text Block]" } } }, "auth_ref": [ "r7", "r10" ] }, "cyd_MaterialCybersecurityIncidentTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Table]" } } }, "auth_ref": [ "r7", "r8" ] }, "cyd_MaterialCybersecurityIncidentTimingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentTimingTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Timing [Text Block]" } } }, "auth_ref": [ "r7", "r10" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.opk.com/20241231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 6-K", "Section": "General Instruction", "Subsection": "B" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "Instruction", "Paragraph": "2" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "a" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" } } } ZIP 19 0001437749-25-008774-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-25-008774-xbrl.zip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opk20241231_10ka_htm.xml IDEA: XBRL DOCUMENT 0000944809 2024-01-01 2024-12-31 0000944809 2024-06-30 0000944809 2025-01-31 iso4217:USD shares true 0000944809 --12-31 FY 2024 10-K/A true 2024-12-31 false 001-33528 OPKO Health, Inc. DE 75-2402409 4400 Biscayne Blvd. Miami FL 33137 305 575-4100 Common Stock OPK NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false false 414913527 671550270 OPKO Health, Inc., a Delaware corporation (the “Company”), is filing this Amendment No. 1 on Form 10-K/A (the “Amendment” or “Form 10-K/A”) to amend and restate Part III, Item 10. Directors, Executive Officers and Corporate Governance to include XBRL tagging and to amend and restate Part IV, Item 15, Exhibits and Financial Statement Schedules of its Annual Report on Form 10-K for the year ended December 31, 2024 originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 3, 2025 (the “Original 10-K”), which inadvertently included the OPKO Health, Inc. Related Party Transaction Policy as Exhibit 19.1 instead of the Company’s Insider Trading Policy. Accordingly, Part IV, Item 15, Exhibits and Financial Statement Schedules has been amended and restated in its entirety to include the Company’s Insider Trading Policy as Exhibit 19.1.   In accordance with Rules 12b-15 and 13a-14 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we have also amended Part IV, Item 15, Exhibits and Financial Statement Schedules to include currently dated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from our principal executive officer and principal financial officer. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. Similarly, because no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted.   Except as described above, this Amendment does not amend, update or change any other disclosures in the Original 10-K. In addition, the information contained in this Amendment does not reflect events occurring after the filing of the Original 10-K and does not modify or update the disclosures therein, except as specifically identified above. Ernst & Young LLP 42 Miami, Florida true